Gene editing-based therapeutic strategies grant the power to override cell machinery and alter faulty genes contributing to disease development like cancer. Nowadays, the principal tool for gene editing is the clustered regularly interspaced short palindromic repeats-associated nuclease 9 (CRISPR/Cas9) system. In order to bring this gene-editing system from the bench to the bedside, a significant hurdle remains, and that is the delivery of CRISPR/Cas to various target cells in vivo and in vitro. The CRISPR-Cas system can be delivered into mammalian cells using various strategies; among all, we have reviewed recent research around two natural gene delivery systems that have been proven to be compatible with human cells. Herein, we have discussed the advantages and limitations of viral vectors, and extracellular vesicles (EVs) in delivering the CRISPR/Cas system for cancer therapy purposes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971689PMC
http://dx.doi.org/10.1038/s41417-023-00597-zDOI Listing

Publication Analysis

Top Keywords

viral vectors
8
vectors extracellular
8
extracellular vesicles
8
delivery systems
8
cancer therapy
8
vesicles innate
4
innate delivery
4
systems utilized
4
utilized crispr/cas-mediated
4
crispr/cas-mediated cancer
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!